115 results about "Cellular energy" patented technology

Therapeutic methods and compositions useful for the prevention and/or treatment of cellular membrane damage leading to or resulting from peroxidation of the cellular membrane and a breakdown of the barrier function of the cellular membrane. A therapeutic composition includes a combination of a membrane sealing sealing surfactant and a cofactor treatment consisting of an antioxidant and a cellular energy store. To affect this goal, the permeability of damaged cellular membranes is reestablished by the membrane sealing surfactant, effectively “sealing” the injured membranes. To facilitate rapid tissue recovery, cellular energy levels can be reestablished through addition of a cellular energy source such as, for example, MgCl₂-ATP which, serves a further dual benefit of improving the cellular ion balance. Addition of an antioxidant eliminates the generation of Reactive Oxygen intermediates and enhances the metabolism of free radicals.

Methods of enhancing the bio-availability of coenzyme Q10, and methods of supporting the cardiovascular system to accommodate the increase in cellular energy synthesis as a result of the bio-availability of coenzyme Q10 are described. Compositions which include coenzyme Q10, lactoferrin and/or angiogenin are described for use in the related methods, for multi-functional health applications.

A method is provided of measuring in vivo of an endogenous fluorophore in a tissue site. A known excitation wavelength of the endogenous flurophore is selected within a range of wavelengths at which the endogenous flurophore undergoes fluorescence. The tissue site is irradiated with irradiated light having at least the selected excitation wavelength within the range of wavelengths. A fluorescence emission of the tissue site resulting from the irradiation thereof is detected. A relative or absolute concentration of the endogenous fluorophore is determined by multiplying it by a calibration factor that depends one at least one of, a known excitation and emission property of the endogenous fluorophore, an intensity of the irradiated light, optical properties of an excitation probe, and specific properties of the tissue. The relative or absolute concentration of the endogenous fluorphore is used to estimate at least one of a, in vivo cellular energy production status or state of end-organ tissue oxygenation.

A composition for enhancing cellular energy that includes creatine, L-arginine-α-ketoglutarate, D-ribose, L-carnitine, L-citrulline, and pyruvate. The composition is administering to a subject to enhance cellular energy, to increase relative intensity of physical activity performed by the subject, to increase endurance of the subject during the physical activity and to increase the muscle mass of the subject.

Consuming water with increased hydrogen content can provide clinical benefits to humans and animals through a non-mitochondria alternative cellular energy (ACE) pathway and also as an antioxidant. This application discloses that the hydrogen content of drinking water can be safely increased by placing into the water a hydrogen generating device, such as a mixture of metallic magnesium and EH-101 (HB-101) containing solution, whereby the device allows for the selective passage of the generated hydrogen but restricts the passage of magnesium and EH-101 (HB-101) components. This partitioning of hydrogen from EH-101 (HB-101) components is achieved by using either reverse osmosis membrane, low density plastic material such as polyvinylidene chloride (PVDC or Saran), or low molecular weight cutoff dialysis membrane to create a sealed container of the magnesium and magnesium chloride, that can be placed into drinkable water. The EH-101 (HB-101) can be initially placed into a breakable inner compartment within the hydrogen permeable container. This compartment can be easily broken by simple squeezing just prior to placing the device into the water that is intended to have its hydrogen content increased. The increased hydrogen content can be assessed by the capacity of the water to decolorize a potassium permanganate test sample.

The present invention is directed to methods of treating a human for a variety of conditions by administering an agonist of the G protein coupled receptor TGR5. In addition, the invention includes methods for determining whether a test compound is likely to be effective in treating one of these conditions by assaying it for its ability to raise intracellular iodothyronine deiodinase levels or for its ability to bind to and activate TGR5.

Consuming water with increased hydrogen content can provide clinical benefits to humans and animals through a non-mitochondria alternative cellular energy (ACE) pathway and also as an antioxidant. This application discloses that the hydrogen content of drinking water can be safely increased by placing into the water a hydrogen generating device, such as a mixture of metallic magnesium and magnesium chloride containing solution, whereby the device allows for the selective passage of the generated hydrogen but restricts the passage of magnesium and magnesium ions. This partitioning of hydrogen from magnesium ions is achieved by using either reverse osmosis membrane or low density plastic material such as polyvinylidene chloride (PVDC or Saran), to create a sealed container of the magnesium and magnesium chloride, that can be placed into drinkable water. The magnesium chloride can be initially placed into a breakable inner compartment within the hydrogen permeable container. This compartment can be easily broken by simple squeezing just prior to placing the device into the water that is intended to have its hydrogen content increased. The increased hydrogen content can be assessed by the capacity of the water to decolorize a potassium permanganate test sample.

A method for treating the disease state in mammals caused by mammalian cells involved in the inflammatory response is disclosed. Mammalian cells participating in the inflammatory response are contacted with an inflammatory suppressor selected from the group consisting of alpha-keto acids and their salts which reduce the undesired inflammatory response and is an antioxidant. The inflammatory suppressor may further provide a cellular energy source and be a building block in the cellular synthesis of other cellular components. Compositions for reducing and treating undesired inflammatory response such as pain, swelling, erythema, crusting, scarring, itching, also disclosed.

This application discloses methods for treating, preventing and/or alleviating the symptoms of type II diabetes and diabetes-related disorders or complications. The invention provides a novel approach to treating and managing disorders and symptoms related to elevated plasma glucose concentrations and insulin resistance, characterized by few side effects and low toxicity. In particular, the invention provides 2-hydroxy-benzoic anilide compounds and derivatives, and compositions thereof, which can control blood-glucose and increase insulin sensitivity by reducing plasma glucose concentration and cellular energy efficiency.

The present invention generally relates to methods and compositions to determine viability of an organ for transplantation and other medical purposes. One aspect of the invention relates to a method for assessing the viability of an organ by measuring the energy parameters to determine the energy level of the organ by determining the stored cellular energy (e.g., ATP levels), and/or energy consumption over a particular time period of viability. The energy parameters can be compared to reference energy parameters as a highly accurate and reliable prediction of viable cell yield, and organ viability. Another aspect of the invention relates methods to preserve or extend the time period of viability of an organ any combination of (i) preservation perfusion of the organ to prevent ischemic damage, (ii) chemical metabolic suppression of the organ e.g., using metabolic suppressants, (iii) metabolic suppression by physical or environmental conditions, e.g., sub-zero non-freezing storage.

The present invention discloses anti-cancer compositions, and associated methods, including an anti-cancer composition comprising: a cellular energy inhibitor having the structure according to formula I

The invention discloses a cellular energy storage container. The cellular energy storage container comprises: a container body, wherein a battery compartment is arranged in the container body, and thebattery compartment is divided into a plurality of unit compartments; battery racks, wherein each unit bin is internally provided with the corresponding battery rack; and heat dissipation devices, wherein each unit bin is internally provided with the corresponding heat dissipation device, each heat dissipation device comprises an air conditioner and an air duct wall, an air outlet of each air conditioner is communicated with an air inlet of the corresponding air duct wall, and an air outlet of each air duct wall faces the battery rack. According to the invention, each unit bin is an independent space, each unit bin is subjected to independent heat dissipation by a heat dissipation device, even if the heat emitted by the battery modules in the unit cabins is inconsistent, the battery modules in the unit cabins can be located in a temperature area with stable performance by adjusting the air volume of the air conditioner and adjusting the temperature of cold air blown out by the air conditioner, and then the performance of the energy storage container is guaranteed on the whole.

The present disclosure relates to compositions and methods that are effective in controlling and preventing bacterial, viral and fungal infections in the living tissue of plants, humans and animals, and in advancing the healing process for wounds to that tissue. The disclosed compositions comprise a biocidal system, a pH buffer, and one or more of a surfactant, a cellular energy supplement, an inflammation reducer, a clotting agent, an electrolytic system, a lattice forming system, and for plants a fungicide, all in an aqueous composition.

The alternative cellular energy (ACE) pathway provides a non-immunological defense mechanism against infectious diseases and can also function as an effective, non-scarring, tissue repair mechanism in response to injury. The ACE pathway can be activated using energy obtained from the ultraviolet light illumination of neutral red dissolved in alcohol. The effectiveness of the alcohol used in this procedure is significantly increased by first bubbling air containing “Water Gas” (otherwise referred to as Brown's Gas or HHO) through the alcohol. The Water Gas is considered as providing an additional charge to the alcohol. Water Gas can similarly be used to charge water and other liquids and to, thereby, increase the liquid's capacity to interact with various dyes, such as neutral red, and with other enerceuticals, which are regarded as being representative of the body's ACE pigments. Various uses are disclosed for using Water Gas charged alcohol and Water Gas charged water, for the therapeutic activation of the ACE pathway.

A transdermal delivery system (TDS) for use in treatment of living bodies may be applied as an open (liquid, gel) or closed (patch) article. The TDS is composed of a particular active agent which dictates an associated selection of certain solvents, solvent modifiers, solute modifiers and skin stabilizers with which the medicament forms a true solution that rapidly crosses the skin barrier. The associated selection of the particular solvents, solvent modifiers, solute modifiers and skin stabilizers is based on a balancing of the molecular properties of all the components against the molecular properties of all the components plus the particular active agent. The TDS includes solvent complex modifiers for regulating the rate of absorption of the active agent. The TDS may also include a source of cellular energy to induce CAMP or cGMP. The TDS improves delivery of active agents having a molecular weight greater than 340 Daltons and increases dosage above 0.25 mg/day for such active agents.

The present invention discloses a cell nutrition enhancing health product preparation and a preparation method thereof, and relates to the technical field of health care products, the cell nutrition enhancing health product preparation is made from the following materials: wall-broken ganoderma lucidum spore powder, selenium-rich yeast, dendrobium officinale freeze-dried powder, ganoderma lucidum extract, astragalus extract, wolfberry extract, rhizoma polygonati powder, Ganoderma sinensis powder, Antrodia powder, American ginseng powder, lentinan, pine pollen, spirulina powder and royal jelly powder, the cell nutrition enhancing health product preparation can activate the electronic delivery system on mitochondrial inner membrane, increase cell mitochondrial ATP production, fundamentally supplement cellular energy, eliminate cell fatigue, and enhance cell regeneration ability, and is free of side effects, by insisting on taking, the cell nutrition enhancing health product preparation helps to enhance physique and improve health state, and is suitable for the sub-health crowd to take.

A bionic composite energy absorption structure with impact angle adaptability comprises micro-cellular energy absorbers which are sequentially arranged in the X direction and the Y direction, whereineach micro-cellular energy absorber comprises a first regular hexagonal prism energy absorber, a second regular hexagonal prism energy absorber and a V-shaped connecting arm. The second regular hexagonal prism energy absorber is arranged in the first regular hexagonal prism energy absorber, and two opposite side edges of the second regular hexagonal prism energy absorber and two opposite side edges of the first regular hexagonal prism energy absorber are located on the same straight line; every two V-shaped connecting arms in the twelve V-shaped connecting arms form a group, one ends of everytwo V-shaped connecting arms are fixed to the side edge of the second regular hexagonal prism energy absorber after being in butt joint, the other ends of the two V-shaped connecting arms are fixed tothe two side faces of the first regular hexagonal prism energy absorber respectively, and six regular hexagonal prism reverse resistance energy absorption units are formed; a hexagonal negative poisson ratio energy absorption unit with the two sides concaved inwards is arranged between every two adjacent regular hexagonal prism reverse resistance energy absorption units. The structure has excellent energy absorption performance under the working conditions of axial and large-angle collision.

The kinetic energy of liquids can be increased by several methods described in the present application. The methods include exposure to a magnetic field provided by a rotating or vibrating magnet; exposure to an electromagnetic field provided by an electrical power cord; and placement of the liquid within the vicinity of electrostatic energy and/or sound energy. A previously described method is the bubbling of electrolysis-generated water gas (Brown's Gas) into the liquid. The increased kinetic energy can be demonstrated using a previously described neutral red dye kinetic assay (NR-Kinetic assay). Energized liquids include alcohol, alcoholic beverages and water. The use of the energized solutions to enhance the alternative cellular energy (ACE) pathway in the therapy of individuals is described.

Alternative cellular energy pigments (ACE-pigments) provide a source of cellular energy other than that provided through the oxidative metabolism of foods, or in the case of plants and certain bacteria, through the process of photosynthesis. In some patients, ACE pigments exist in a form that can be further energized or activated using ultraviolet (UV) light, especially if the reaction is initially triggered by the presence of suitable dyes, such as neutral red. A method is described to further enhance the activation of the ACE pathway in humans and animals deprived of ACE. The method comprises using natural or man-made sources of ACE products (enerceuticals), with or without the inclusion of a suitable dye, such as neutral red; or other activating components, such as magnesium chloride; with the combined mixture being put into a UV transparent container, such as a plastic bag, or placed on some other material, which can be laid onto the skin and illuminated with a UV light source. The process of activating the ACE pathway is evidenced by UV inducible fluorescence seen within areas of the patients' skin and/or mucus membranes. This fluorescence fades as the ACE pathway becomes fully activated. Activating the ACE pathway can have therapeutic benefits in various infectious and non-infectious diseases including illnesses attributed to infections with stealth adapted and conventional viruses and diseases attributed to an inadequacy of the mitochondria and associated metabolic pathways, including states of hypoxia and nutritional deficiencies.

The present invention relates to the use of methyl pyruvic acid (a methyl ester of pyruvic acid) and/or methyl pyruvate (methyl pyruvate is the ionized form of methyl pyruvic acid) for the purpose of increasing cellular energy production thereby providing energy for the continuous activation of PARP-1 and up-regulation of PPAR. It is well known that chronic activation of PARP causes ATP and NAD depletion with concomitant cell death. PARP is known to prevent HIV replication by competitive receptor inhibition. Use of methyl pyruvate and/or methyl pyruvic acid can be effective when administered orally or infused on either a chronic and/or acute basis. In the following text, the terms “methyl pyruvate, methyl pyruvate compounds, methyl pyruvic acid” are used interchangeably.

The invention discloses coenzyme Q10 capsules and preparation technology thereof. The coenzyme Q10 capsules comprise, 6-10% of coenzyme Q10, 78-85% of microcrystalline cellulose, 8-11% of dextrin, and 1-2% of silica. The preparation technology is simple, and the prepared capsules can activate nutrition of cells of the human body and cell energy, and have the function of improving immunity of the human body, enhancing oxidation resistance, delaying aging and improving vitality of the human body.

The invention relates to the technical field of skin care products, in particular to a composition and an application thereof to preparation of skin care products to repair of damaged skin and musclecaused by staying up late or all night. The composition provided by the invention comprises adenosine, a leucojum aestivum bulb extract and sodium hyaluronate. Through interaction and inter-promotionof the components, favorable effects of replenishing water, moisturizing, restoring skin glossiness, promoting cell energy synthesis, and promoting cell proliferation are realized. The composition isused for preparing cosmetics, so that a series of problems of skin and muscle of people staying up late or all night can be solved.

Application for MDR TNBC significantly increasing the efficacy of TNBC treatment and address a global health concern by blocking the ability of mitochondria to fuse together and with other organelles through a nanomedicine therapy. The development of a dual targeted nanomedicine therapy targeting the epidermal growth factor receptor on the surface of TNBC cancers cells and subcellular targeting of mitochondria through mitofusin 2 (MFN2) targeting (mitofusin mediates inter-mitochondrial fusion and fusion of mitochondria with the endoplasmic reticulum). The combination therapy delivers an MFN2-peptidepolymer construct for blocking MFN2 along with a low dose of BAM? (a BAX activator). Transient blocking of MFN2 reduces cellular energy capacity (through decreased mitochondrial fusion), decrease total protein production (by decreased mitochondrial coupling to the endoplasmic reticulum), increases the susceptibility of the cell to paclitaxel or BAM? (increased efficacy of lower dose), with minimal toxicity to normal cells (as IVIFN2 blocking inhibits mitochondrial fusion not mitochondrial function).